Organization
West Cancer Center & Research Institute
11 abstracts
Abstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS).Org: Tennessee Oncology, PLLC, Chattanooga, TN, Nashville, West Cancer Center & Research Institute,
Abstract
Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, West Cancer Center & Research Institute, Novocure Inc., NovoCure, Na Homolce Hospital,
Abstract
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.Org: West Cancer Center & Research Institute, University of Chicago, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital,
Abstract
Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, Department of Preventive Medicine,
Abstract
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,
Abstract
Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.Org: Georgetown University Medical School, Genentech, Genesis Research Group, Genentech Inc., West Cancer Center & Research Institute,
Abstract
A randomized controlled trial of a mobile app and tailored messages to improve outcomes among women with breast cancer receiving adjuvant endocrine therapy.Org: Ovation.io, West Cancer Center & Research Institute, University of Nevada, Reno,
Abstract
Treatment outcomes in patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver.Org: West Cancer Center & Research Institute, Merck, Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany,
Abstract
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification.Org: West Cancer Center & Research Institute, Merck, ConcertAI,